Barbosa-Cobos RE, Ramos-Cervantes MT, De Montesinos-Sampedro A, Rodríguez-Ballesteros DC, García-Moreno-Mutio SL, Jaimes-Santoyo J, Lugo-Zamudio GE, Becerril-Mendoza LT, González-Ramírez LV, Ocharán-Hernández ME, Beltrán-Ramírez O, Toscano-Garibay J

Idioma: Español
Referencias bibliográficas: 29
Paginas: 49-54
Archivo PDF: 203.40 Kb.

RESUMEN

La sustancia P (SP) es un neuropéptido miembro de la familia de las taquicininas, cuya acción se ejerce mediante la unión al receptor neurocinina-1 perteneciente a la superfamilia de receptores acoplados a proteínas G, se sintetiza en el cuerpo celular de los nervios periféricos y posteriormente se distribuye en el sistema nervioso central y periférico, también se produce en células no neuronales como células endoteliales, macrófagos, granulocitos, linfocitos y células dendríticas. Este neuropéptido es un potente mediador de la inflamación neurogénica que está involucrado en el eje neuroinmune y en reacciones inflamatorias de distintos órganos y sistemas. Se ha demostrado su participación en modelos experimentales de artritis y se ha documentado un incremento en los niveles del líquido sinovial, plasma y suero de pacientes con artritis reumatoide. En esta revisión se presentan los hallazgos que sugieren que la SP juega un papel crítico en la inflamación articular.

REFERENCIAS (EN ESTE ARTÍCULO)

1. O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201: 167-80.

2. Fernandes ES, Schmidhuber SM, Brain SD. Sensory-nervederived neuropeptides: possible therapeutic targets. Handb Exp Pharmacol 2009; 194: 393-416.

3. Chadwick D, Goode J (edS). Osteoarthritic joint pain. UK: JohnWiley & Sons Ltd;2004.

4. Brain SD, Cox HM. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 2006; 147(Suppl. 1): S202-s211.

5. O’Shaughnessy MC, Vetsika EK, Inglis JJ, Carleson J, Haigh R, Kidd BL, Winyard PG. The effect of substance P on nitric oxide release in a rheumatoid arthritis model. Inflamm Res 2006; 55: 236-40.

6. Cattaruzza F, Poole DP, Bunnett NW. Arresting inflammation: contributions of plasma membrane and endosomal signalling to neuropeptide-driven inflammatory disease. Biochem Soc Trans 2013; 41: 137-43.

7. Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in pancreatic cancer. World J Gastroenterol 2014; 20: 2321-34.

8. Roux BT, Cottrell GS. G protein-coupled receptors: what a difference a ‘partner’ makes. Int J Mol Sci 2014; 15: 1112-42.

9. Garrett NE, Mapp PI, Cruwys SC, Kidd BL, Blake DR. Role of substance P in inflammatory arthritis. Ann Rheum Dis 1992; 51: 1014-8.

10. Zhang B, Muneta T, Yagishita K, Sekiya I. Substance P immunoreactive fibers of synovial tissue in patients with anterior cruciate ligament injury. Knee Surg Sports Traumatol Arthrosc 2006; 14: 404-10.

11. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002; 302: 839-45.

12. Verdrengh M, Tarkowski A. The impact of substance P signalling on the development of experimental staphylococcal sepsis and arthritis. Scand J Immunol 2008; 67: 253-9.

13. Ramalho R, Soares R, Couto N, Moreira A. Tachykinin receptors antagonism for asthma: a systematic review. BMC Pulm Med 2011; 11: 41.

14. Vatrella A, Montagnani S, Calabrese C, Parrella R, Pelaia G, Biscione GL, et al. Neuropeptide expression in the airways of COPD patients and smokers with normal lung function. J Biol Regul Homeost Agents 2010; 24: 425-32.

15. Tavano F, di Mola FF, Latiano A, Palmieri O, Bossa F, Valvano MR. Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels. J Crohns Colitis 2012; 6: 563-70.

16. Peters EM, Ericson ME, Hosoi J, Seiffert K, Hordinsky MK, Ansel JC, et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol 2006; 126: 1937-47.

17. Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc 2011; 15: 33-9.

18. Mijouin L, Hillion M, Ramdani Y, Jaouen T, Duclairoir-Poc C, Follet-Gueye ML, et al. Effects of a skin neuropeptide (substance p) on cutaneous microflora. PLoS One 2013; 8: e78773.

19. Teresiak-Mikolajczak E, Czarnecka-Operacz M, Jenerowicz D, Silny W. Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus. Postepy Dermatol Alergol 2013; 30: 286-92.

20. Mantelli F, Micera A, Sacchetti M, Bonini S. Neurogenic inflammation of the ocular surface. Curr Opin Allergy Clin Immunol 2010; 10(5): 498-504.

21. Kidd BL, Mapp PI, Blake DR, Gibson SJ, Polak JM. Neurogenic influences in arthritis. Ann Rheum Dis 1990; 49: 649-52.

22. Bulling DG1, Kelly D, Bond S, McQueen DS, Seckl JR. Adjuvant-induced joint inflammation causes very rapid transcription of beta-preprotachykinin and alpha-CGRP genes in innervating sensory ganglia. J Neurochem 2001; 77: 372-82.

23. Makino A, Sakai A, Ito H, Suzuki H. Involvement of tachykinins and NK1 receptor in the joint inflammation with collagen type II-specific monoclonal antibody-induced arthritis in mice. J Nippon Med Sch 2012; 79: 129-38.

24. Tanabe T, Otani H, Mishima K, Ogawa R, Inagaki C. Mechanisms of oxyradical production in substance P stimulated rheumatoid synovial cells. Rheumatol Int 1996; 16: 159-67.

25. Seegers HC, Hood VC, Kidd BL, Cruwys SC, Walsh DA. Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation. J Pharmacol Exp Ther 2003; 306: 8-12.

26. Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol 1993; 32: 31-5.

27. Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, Tamai M, et al. Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. Mod Rheumatol 2011; 21: 244-50.

28. Grimsholm O, Rantapää-Dahlqvist S, Forsgren S. Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R416-R426.

29. Green PG. Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis. Arthritis Res Ther 2005; 7: 111-3.